Search research articles
Contact Us
Filters
Showing results (91-100 of 96) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 96 results.
Nature Medicine
|
July 1, 2026
Innate immune responsiveness predicts enhanced cellular immunity and symptomatic disease after controlled human influenza infection
Loukas Papargyris, Jiayun Xu, Claire Broderick, et al.
Nature Communications
|
April 26, 2020
Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts
Kwanghee Kim, Wenhuo Hu, François Audenet, et al.
Vaccine
|
September 6, 2024
Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial
Xuan Ying Poh, Anthony Torres-Ruesta, Terence Yoong, et al.
Ebiomedicine
|
August 13, 2024
First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial
Xuan Ying Poh, I Russel Lee, Chee Wah Tan, et al.
The Lancet Regional Health. Western Pacific
|
May 1, 2023
Heterologous mRNA vaccine boosters induce a stronger and longer-lasting antibody response against Omicron XBB variant
Matthew Zirui Tay, Yun Shan Goh, Siew-Wai Fong, et al.
Journal of Medical Virology
|
October 28, 2022
Efficient recall of SARS-CoV-2 variant-reactive B cells and T responses in the elderly upon heterologous mRNA vaccines as boosters
Angeline Rouers, Nathan Wong, Yun Shan Goh, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 96) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 96 results.
Nature Medicine
|
July 1, 2026
Innate immune responsiveness predicts enhanced cellular immunity and symptomatic disease after controlled human influenza infection
Loukas Papargyris, Jiayun Xu, Claire Broderick, et al.
Nature Communications
|
April 26, 2020
Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts
Kwanghee Kim, Wenhuo Hu, François Audenet, et al.
Vaccine
|
September 6, 2024
Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial
Xuan Ying Poh, Anthony Torres-Ruesta, Terence Yoong, et al.
Ebiomedicine
|
August 13, 2024
First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial
Xuan Ying Poh, I Russel Lee, Chee Wah Tan, et al.
The Lancet Regional Health. Western Pacific
|
May 1, 2023
Heterologous mRNA vaccine boosters induce a stronger and longer-lasting antibody response against Omicron XBB variant
Matthew Zirui Tay, Yun Shan Goh, Siew-Wai Fong, et al.
Journal of Medical Virology
|
October 28, 2022
Efficient recall of SARS-CoV-2 variant-reactive B cells and T responses in the elderly upon heterologous mRNA vaccines as boosters
Angeline Rouers, Nathan Wong, Yun Shan Goh, et al.
Page
of 10